
    
      It is an open, single-arm, multi-center clinical trial conducted in China, and plan to
      Recruiting103 patients who were progressed after first line systemic therapy and
      refused/can't tolerate chemotherapy. Patents receive 12mg anlotinib orally daily on day 1to
      14 of a 21-day cycle until progression of disease, assess safety and efficacy of the drug.
    
  